Agenus Profile

3.55
USD 0.02  0.56%
0%
43%

Acquisition by Dechaene Tom of 686 shares of Agenus subject to Rule 16b-3

Agenus insider trading alert for grant of deferred shares by Dechaene Tom, the corporate stakeholder, on April 26, 2018. This event was filed by Agenus Inc with SEC on 2013-01-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Agenus Summary

Agenus (AGEN) is traded on Nasdaq Capital Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 255 people. Agenus is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 387.67 M. Agenus conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 102.56 M outstanding shares of which 10.35 M shares are presently shorted by private and institutional investors with about 4.43 trading days to cover. ANTIGENICS INC currently holds about 60.19 M in cash with (94.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59.
Check Agenus Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
under 4%30 days 3.55  roughly 96.0%
Based on normal probability distribution, the odds of Agenus to move above current price in 30 days from now is roughly 96.0% (This Agenus probability density function shows the probability of Agenus Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fisher Asset Management LlcCommon Shares379.2 K1.8 M
Fox Run Management LlcCommon Shares43.2 K203 K
View Agenus Diagnostics

Selected Agenus Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Agenus Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 93% 
Equity ratings for Agenus are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodys immune system to fight cancer. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 255 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameAgenus
ChairmanGaro ArmenView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationMASSACHUSETTS, U.S.A
Business Address3 Forbes Road
ExchangeNasdaq Capital Markets
CIK Number01098972.0
CUSIP00847G705
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websiteagenusbio.com
Contact Number781 674 4400
CurrencyUSD - US Dollar

Recommendations

Agenus Analyst Recommendations
Target PriceAdvice# of Analysts
6.33Buy3Odds
Agenus current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Agenus Analyst Advice  

Earnings

Agenus Earnings Estimates
Agenus normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Agenus Corporate Directors
Ulf Wiinberg Director
Shalini Sharp Director
Wadih Jordan Independent Director
Check also Trending Equities. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.